Last reviewed · How we verify
TCI507
TCI507 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses.
TCI507 is a monoclonal antibody that targets and inhibits IL-6 signaling to reduce inflammatory responses. Used for Inflammatory conditions associated with elevated IL-6.
At a glance
| Generic name | TCI507 |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | IL-6 inhibitor monoclonal antibody |
| Target | IL-6 or IL-6 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TCI507 binds to interleukin-6 (IL-6) or its receptor, blocking the IL-6 inflammatory pathway. This mechanism reduces systemic inflammation and is used in conditions characterized by elevated IL-6-mediated immune activation. The drug has been developed and marketed by National Taiwan University Hospital for inflammatory and autoimmune conditions.
Approved indications
- Inflammatory conditions associated with elevated IL-6
Common side effects
- Infection
- Infusion reactions
- Elevated liver enzymes
Key clinical trials
- The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults (NA)
- The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCI507 CI brief — competitive landscape report
- TCI507 updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI